Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E26.58 EPS (ttm)2.80 Insider Own9.30% Shs Outstand2.64B Perf Week-1.56%
Market Cap196.25B Forward P/E14.43 EPS next Y5.16 Insider Trans0.26% Shs Float2.53B Perf Month-0.48%
Income6.71B PEG4.32 EPS next Q1.14 Inst Own10.70% Short Float0.22% Perf Quarter7.79%
Sales49.44B P/S3.97 EPS this Y-2.80% Inst Trans4.50% Short Ratio1.62 Perf Half Y-6.04%
Book/sh31.55 P/B2.36 EPS next Y9.77% ROA5.10% Target Price91.20 Perf Year5.15%
Cash/sh2.95 P/C25.24 EPS next 5Y6.15% ROE9.10% 52W Range64.58 - 80.64 Perf YTD5.82%
Dividend2.75 P/FCF92.53 EPS past 5Y-5.80% ROI7.30% 52W High-7.78% Beta0.78
Dividend %3.70% Quick Ratio0.80 Sales past 5Y-3.60% Gross Margin65.10% 52W Low15.16% ATR0.78
Employees118393 Current Ratio1.10 Sales Q/Q-1.50% Oper. Margin16.40% RSI (14)51.15 Volatility0.97% 0.88%
OptionableYes Debt/Eq0.32 EPS Q/Q-8.00% Profit Margin13.60% Rel Volume0.48 Prev Close74.43
ShortableYes LT Debt/Eq0.24 EarningsApr 26 BMO Payout96.30% Avg Volume3.40M Price74.37
Recom2.00 SMA20-1.00% SMA502.28% SMA2000.64% Volume1,637,449 Change-0.08%
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Mar-24-17 05:05PM  Exploring Novartiss 2016 Revenue
03:07PM  Novartiss Valuation Compared to Its Peers
11:00AM  Novartis Licenses 2 Drugs In Exchange for Equity at Investopedia
07:47AM  Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
Mar-23-17 09:06AM  New Product Launches May Boost Valeants Dermatology Revenue
08:26AM  Novartis' Intraocular Lens Secures FDA Approval (NVS) at Investopedia
Mar-22-17 06:12PM  Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
04:51PM  Novartis cancer drug combo developed partly in Cambridge shows early promise at bizjournals.com
04:17PM  Novartis Heart Drug Flops In Second Late-Stage Trial As Expected
12:07PM  Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials
08:52AM  Novartis Heart Drug Fails Late Stage Trials (NVS, AZN) at Investopedia
Mar-21-17 09:50AM  Does Novartis (NVS) Stock Make a Good Value Pick?
09:18AM  6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
07:51AM  Novartis Cosentyx Shows Psoriasis Modification Potential (NVS, DERM) at Investopedia
07:00AM  Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks at Morningstar
Mar-20-17 06:22PM  Novartis (NVS) Announces Positive Data on Heart Failure Drug
01:18PM  Why Amgen's Success Was a Big Disappointment at Motley Fool
01:16PM  Eli Lilly Breast Cancer Combo Does Well In Trial at Investopedia
09:06AM  Novartis Heart Failure Drug Beats Enalapril (NVS) at Investopedia
Mar-17-17 07:38AM  A Look at Opdivos Performance in 2016
Mar-16-17 02:51PM  Flexi-Pricing Scheme Unveiled For Novartis AG (ADR) (NVS) Kisqali In The Face Of Stiff Competition at Insider Monkey
11:15AM  Novartis AG :NVS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
Mar-15-17 03:41PM  Will Pfizer's Growth Be Threatened by Novartis' New Cancer Drug? at Motley Fool
10:24AM  Novartis Introduces Flexible Pricing for Kisqali at Investopedia
08:09AM  Turning Pfizer Discards Into Novartis Gold: The Story Of Ziarco at Forbes
Mar-14-17 05:41PM  Novartis Takes Aim at Pfizer in Breast Cancer at Motley Fool
04:14PM  Novartis Breast Cancer Drug Just OK'd And Already Losing?
01:52PM  AstraZeneca PLC (ADR) (AZN) Rejected Drugs To Be Reconsidered at Insider Monkey
10:55AM  Gilead Looking To Buy Incyte? It Makes Sense
10:41AM  Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
10:13AM  Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance Reuters
09:51AM  Novartis Breast Cancer Drug Gets FDA Approval at Investopedia
12:03AM  AstraZeneca Gives Rejected Drugs a Second Life at The Wall Street Journal
Mar-13-17 07:28PM  FDA OKs new Novartis drug for type of advanced breast cancer
05:17PM  Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval Business Wire
05:00PM  FDA approves Novartis drug as first-line treatment for breast cancer Reuters
09:53AM  [$$] AstraZeneca Gives Rejected Drugs a Second Life at The Wall Street Journal
Mar-10-17 01:37PM  Novartis AG :NVS-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017
07:51AM  How Incyte Stock Became a Bull Market Star for Biotech Investors
Mar-09-17 09:03AM  5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade at Motley Fool
08:49AM  Coverage initiated on Novartis AG by Liberum
Mar-08-17 11:00AM  Positive Results For AbbVie Inc (ABBV) Humira Biosimilar Reported By Novartis AG (ADR) (NVS) at Insider Monkey
Mar-07-17 04:21PM  Novartis (NVS) Reports Positive Data on Biosimilar Humira
07:04AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis at Motley Fool
Mar-06-17 01:10PM  RBC Hints At Potential M&A For Kite Pharma
04:09AM  Novartis Division Sandoz Announces Proposed Biosimilar Adalimumab Shown to have Equivalent Efficacy, Similar Safety Profile as Humira
Mar-03-17 11:42AM  Novartis AG (ADR) (NVS) Fined And Some Products To Be Temporarily Suspended In South Korea at Insider Monkey
Mar-02-17 07:58AM  Novartis Shares Lower on Ex Dividend Trading, Reports of Kickbacks Fine In South Korea
04:48AM  South Korea fines Novartis over kickbacks, suspends sales of some drugs Reuters
Mar-01-17 11:33AM  Lexicon Stock Spikes 8% on Diarrhea Drug Approval at Investopedia
09:40AM  Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss
09:06AM  A Look at Incytes Product Portfolio
07:36AM  Growth of AstraZenecas Oncology Segment in 2016
Feb-28-17 02:35PM  Understanding Incytes Revenue Stream for 2016
12:12PM  Roche Attempts New Trial for Alzheimer's at Investopedia
08:16AM  Gene therapy to fight a blood cancer succeeds in major study
07:24AM  Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
Feb-27-17 10:14AM  Novartis Shows the World a Take of 2 Charts
Feb-24-17 11:21AM  Novartis Lung Cancer Drug Combo Gets CHMP Nod at Investopedia
11:05AM  Novartis Cancer Drug Zykadia Gets Priority Review at Investopedia
08:15AM  Blog Coverage Novartis Gains Priority Review from the FDA for its Cancer Drug Zykadia as a Frontline Treatment for ALK-positive Non-Small Cell Lung Cancer Accesswire
07:35AM  Ring the Register With These Upcoming Spinoffs
07:27AM  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
06:00AM  Morningstar's 5 Favorite Foreign-Stock ETFs at Morningstar
Feb-23-17 05:06PM  Teva Is Expected to See a Fall in Its Profit Margins in 2017
10:35AM  Medford's Seventh Sense wins narrow FDA approval for blood-collection device at bizjournals.com
09:24AM  Januvia and Janumet: Merck & Co.s Blockbuster Diabetes Products
08:04AM  5 reasons to invest in European stocks now at MarketWatch
08:02AM  Here's Why Celgene's Latest Drug Is So Exciting at Motley Fool
Feb-22-17 03:01PM  In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs at bizjournals.com
10:37AM  Keytruda: Mercks Immuno-Oncology Blockbuster Drug
Feb-21-17 12:37PM  Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug
12:26PM  Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today at Motley Fool
Feb-20-17 07:37AM  This Keeps Driving Sanofis Growth
Feb-18-17 12:09PM  2 High-Yield Dividend Stocks That Are Ridiculously Cheap at Motley Fool
Feb-17-17 04:46PM  Inside Sanofis Revenues in 4Q16
08:15AM  Blog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis Following Clearance under the Hart-Scott-Rodino Antitrust Improvements Act Accesswire
07:37AM  Prolia Expected to Be a Significant Growth Driver for Amgen in 2017
Feb-16-17 09:27AM  Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
09:05AM  GlaxoSmithKlines Valuation Compared to Its Peers
Feb-15-17 12:38PM  Bristol-Myers: Don't Bet on a Pfizer Acquisition at Barrons.com
Feb-14-17 03:33PM  Bristol-Myers Squibb: Takeover Target? at Barrons.com
01:35PM  4Q16 Performance of GlaxoSmithKlines Business Segments
11:13AM  Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education at Insider Monkey
02:00AM  These N.Y.C.-area doctors received the most payments from drug and device makers at bizjournals.com
Feb-10-17 04:10PM  Intercept Bounds To 3-Month High On NASH Trial Edits; Analysts Split
10:43AM  10 Most Diverse Companies In The US at Insider Monkey
08:22AM  Is Array BioPharma the Best Clinical-Stage Biotech Stock to Buy in 2017? at Motley Fool
Feb-09-17 10:15AM  UBS Makes First Big 2017 Addition to Dividend Rulers Stocks List
Feb-08-17 06:00AM  Propeller Health Enters into Collaboration to Connect Breezhaler Devices to the Propeller Platform PR Newswire
Feb-03-17 10:36AM  Novartiss Valuation after the 4Q16 Results
09:06AM  Why the Majority of Analysts Deem Novartis a Buy
07:36AM  Novartiss Financial Guidance and Priorities for 2017
Feb-02-17 10:37AM  Novartiss Recent Developments
09:49AM  Novartis (NVS) Votubia Gets EU Approval for Label Expansion
09:07AM  Inside Novartiss Eye Care Performance in 4Q16
07:37AM  Inside Novartiss Generics Performance in 4Q16
06:42AM  GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
Feb-01-17 05:20PM  Novartis Has Bright Future
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Innovative Medicines, Sandoz, and Alcon. The Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and with Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerMar 15Buy5.00560,0002,800,0005,805,550Mar 17 08:36 PM
Novartis Bioventures Ltd10% OwnerOct 31Buy13.0084,6151,099,9952,545,652Oct 31 04:50 PM
Novartis Bioventures Ltd10% OwnerOct 31Sale13.003394,40762,575Oct 31 04:50 PM
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM